MERIT MEDICAL SYSTEMS INC
Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.
Peterson Neil W. (CHIEF OPERATING OFFICER) sold 21,449 shares of MERIT MEDICAL SYSTEMS INC (MMSI) at $85.00 ($1.82M total) on 2026-08-04.
Merit Medical Systems reported Q2 revenue of $418.8M, above analysts’ $405.3M estimate, and adjusted EPS of $1.19 versus $0.96. The company slightly raised full-year revenue guidance to $1.64B and adjusted EPS to $4.30 at the midpoint. Management cited Biolife and C2 integration, oncology launches (OneMark, SCOUT MD), and margin gains.
Over the past 7 days, alphai's AI scored 2 news stories mentioning MMSI (MERIT MEDICAL SYSTEMS INC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent MMSI coverage spans earnings, financial news and insider activity.
In the last 30 days, MMSI insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.8M). The most active reporter was Peterson Neil W., CHIEF OPERATING OFFICER, with 1 filing.
Guidance raises and margin/EPS beats suggest improving fundamentals, with near-term focus on Q3 revenue/EPS ranges and tariff and recall-related normalization.
The filing is a routine insider sale with no 10b5-1 plan stated, but it does not disclose new company fundamentals.
Guidance raises plus margin expansion from integration and oncology launches suggest improving fundamentals, supporting a constructive near-term bias while tariff risk remains a swing factor.
Raised full-year guidance after a strong Q2 beat should support near-term estimates and sentiment, with upside risk if demand holds.
Beat on revenue and adjusted EPS plus full-year revenue guidance modestly above consensus likely supports near-term upside momentum, though margin contraction in the quarter is a caution.
alphai scores every news story that mentions MMSI with an AI model for sentiment and relevance, and aggregates insider trades from MERIT MEDICAL SYSTEMS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.
6 min readPeterson Neil W. (CHIEF OPERATING OFFICER) sold 21,449 shares of MERIT MEDICAL SYSTEMS INC (MMSI) at $85.00 ($1.82M total) on 2026-08-04.
1 min readMerit Medical Systems reported Q2 revenue of $418.8M, above analysts’ $405.3M estimate, and adjusted EPS of $1.19 versus $0.96. The company slightly raised full-year revenue guidance to $1.64B and adjusted EPS to $4.30 at the midpoint. Management cited Biolife and C2 integration, oncology launches (OneMark, SCOUT MD), and margin gains.
6 min readMerit Medical Systems Inc (NASDAQ:MMSI) posted better-than-expected earnings for the second quarter on Thursday. The company posted adjusted EPS of $1.19, beating market estimates of 96 cents per share. The company’s sales came in at $418.843 million versus expectations of $405.268 million. Merit Medical Systems raised its FY2026 adjusted EPS guidance from $4.01-$4.15 to $4.25-$4.35 and increased its sales forecast from $1.612 billion-$1.634 billion to $1.631 billion-$1.643 billion.
3 min readMedical device company Merit Medical Systems (NASDAQ: MMSI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates. Is now the time to buy Merit Medical Systems? Find out by accessing our full research report, it’s free.
4 min readMERIT MEDICAL SYSTEMS INC (MMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmsi-20260730xex99d1.htm EX-99.1 Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-801-432-2864 +1-443-213-0509 sarah.comstock@merit.com mike.piccinino@i
6 min readMerit Medical Systems (NASDAQ: MMSI) is set to report Q2 earnings Thursday after the bell. The company previously reported $381.9 million revenue, up 7.5% year over year, and beat EPS and full-year EPS guidance. For the upcoming quarter, analysts expect revenue growth of about 6% y/y. MMSI has an average analyst price target of $90.09 versus $78.29.
3 min readMerit Medical Systems (NASDAQ: MMSI) said it will report second-quarter 2026 results for the quarter ended June 30, 2026 after the market close on July 30, 2026. The company will host an investor conference call that day at 4:30 p.m. ET, with a live webcast and slide deck available on its website.
2 min readMerit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue for Q4 CY2025, with sales up 10.9% year-on-year to $393.9 million, surpassing analyst estimates. Both the full-year revenue guidance and adjusted EBITDA also beat expectations, although non-GAAP profit for the quarter slightly missed consensus estimates. The company showed strong operating margin improvement and impressive long-term EPS growth, despite a minor miss on quarterly adjusted EPS.
3 min readMerit Medical Systems, Inc. (NASDAQ:MMSI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $105.88. The company recently reported strong quarterly earnings and revenue, surpassing analyst estimates, and has set optimistic full-year 2025 guidance. Despite recent insider selling, institutional investors hold a significant portion of the stock.
3 min read
